ASN-RASAGILINE TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

RASAGILINE (RASAGILINE MESYLATE)

Доступна з:

ASCEND LABORATORIES LTD

Код атс:

N04BD02

ІПН (Міжнародна Ім'я):

RASAGILINE

Дозування:

1MG

Фармацевтична форма:

TABLET

Склад:

RASAGILINE (RASAGILINE MESYLATE) 1MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

100

Тип рецепту:

Prescription

Терапевтична области:

MONOAMINE OXIDASE B INHIBITORS

Огляд продуктів:

Active ingredient group (AIG) number: 0151662002; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2019-06-04

Характеристики продукта

PRODUCT MONOGRAPH
Pr
ASN-RASAGILINE
RASAGILINE MESYLATE
0.5 MG AND 1 MG RASAGILINE TABLETS (AS RASAGILINE MESYLATE)
ANTIPARKINSON AGENT
Ascend Laboratories Ltd.
35 Nixon Road, Unit 10
Caledon, Ontario
L7E 1K1
Date of Preparation:
May 30, 2019
Control Number: 221339
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
..........................................................................................................23
DETAILED PHARMACOLOGY
.....................................................................................28
T